{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:35:51Z","timestamp":1777361751711,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.vaccine.2008.05.072","type":"journal-article","created":{"date-parts":[[2008,6,18]],"date-time":"2008-06-18T08:43:59Z","timestamp":1213778639000},"page":"4178-4186","source":"Crossref","is-referenced-by-count":32,"title":["Safety and immunogenicity of CRM197-conjugated pneumococcal\u2013meningococcal C combination vaccine (9vPnC\u2013MnCC) whether given in two or three primary doses"],"prefix":"10.1016","volume":"26","author":[{"given":"Sigurveig Th.","family":"Sigurdardottir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Davidsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilhjalmur A.","family":"Arason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Laudat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingileif","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2008.05.072_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10096-006-0092-4","article-title":"Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis","volume":"25","author":"Obonyo","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. 2(2)","key":"10.1016\/j.vaccine.2008.05.072_bib2","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1007\/s00431-002-1064-z","article-title":"Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California","volume":"161","author":"Black","year":"2002","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2008.05.072_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9465","key":"10.1016\/j.vaccine.2008.05.072_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.vaccine.2008.05.072_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"issue":"9381","key":"10.1016\/j.vaccine.2008.05.072_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(03)14022-6","article-title":"Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial","volume":"362","author":"O\u2019Brien","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2008.05.072_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"issue":"24","key":"10.1016\/j.vaccine.2008.05.072_bib8","article-title":"Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults","volume":"Suppl. 2","author":"Black","year":"2006","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2008.05.072_bib9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"issue":"9559","key":"10.1016\/j.vaccine.2008.05.072_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)60195-0","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis","volume":"369","author":"Sinha","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2008.05.072_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2008.05.072_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00006454-200206000-00013","article-title":"Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine","volume":"21","author":"Sigurdardottir","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2008.05.072_bib13","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1086\/515298","article-title":"Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines","volume":"177","author":"Anttila","year":"1998","journal-title":"J Infect Dis"},{"issue":"15\u201316","key":"10.1016\/j.vaccine.2008.05.072_bib14","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/S0264-410X(98)00458-7","article-title":"Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood","volume":"17","author":"Anttila","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2008.05.072_bib15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2008.05.072_bib16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CDLI.2.5.590-597.1995","article-title":"Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S","volume":"2","author":"Quataert","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1 Suppl.","key":"10.1016\/j.vaccine.2008.05.072_bib17","first-page":"S84","article-title":"Standardization of antibody assays for measuring the response to pneumococcal infection and immunization","volume":"8","author":"Siber","year":"1989","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2008.05.072_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CDLI.10.4.514-519.2003","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2008.05.072_bib19","first-page":"289","article-title":"Assessment of functional antibody responses","volume":"87","author":"Borrow","year":"2003","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.vaccine.2008.05.072_bib20","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.05.072_bib21","unstructured":"Helga Erlendsd\u00f3ttir MG, Karl G. Kristinsson. [Hj\u00fapger\u00f0ir \u00edfarandi pneum\u00f3kokka \u00e1 \u00cdslandi og tengsl \u00feeirra vi\u00f0 aldursh\u00f3pa og d\u00e1nart\u00ed\u00f0ni] Icelandic. The Icelandic Medical Journal 2002;88(Suppl. 47):22."},{"issue":"9546","key":"10.1016\/j.vaccine.2008.05.072_bib22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2008.05.072_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.inf.0000151022.92222.be","article-title":"Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age","volume":"24","author":"Kayhty","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2008.05.072_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.inf.0000207483.60267.e7","article-title":"Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers","volume":"25","author":"Goldblatt","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.05.072_bib25","unstructured":"Dagan R, Abu-Abed J, Rosenblum H, Greenberg D. Nasopharyngeal pneumococcal carriage (NPC) in first year of life following administration of two or three doses of 7-valent CRM-conjugate vaccine (PCV7). ICAAC [Abstract # G-1241], Chicago; 2007."},{"issue":"12","key":"10.1016\/j.vaccine.2008.05.072_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-8-12","article-title":"Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age","volume":"8","author":"Esposito","year":"2007","journal-title":"Respir Res"},{"issue":"14","key":"10.1016\/j.vaccine.2008.05.072_bib27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jama.293.14.1751","article-title":"Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial","volume":"293","author":"Buttery","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2008.05.072_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2567.2006.02436.x","article-title":"The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine","volume":"119","author":"Clutterbuck","year":"2006","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.vaccine.2008.05.072_bib29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1128\/IAI.67.5.2366-2370.1999","article-title":"Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides","volume":"67","author":"Usinger","year":"1999","journal-title":"Infect Immun"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2008.05.072_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/jmm.0.46579-0","article-title":"Control of pneumococcal disease in the United Kingdom\u2014the start of a new era","volume":"55","author":"Clarke","year":"2006","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.05.072_bib31","first-page":"E060302 4","article-title":"Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules","volume":"11","author":"Cameron","year":"2006","journal-title":"Euro Surveill"},{"issue":"2","key":"10.1016\/j.vaccine.2008.05.072_bib32","article-title":"Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme","volume":"11","author":"Bergsaker","year":"2006","journal-title":"Euro Surveill"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0800683X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0800683X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T10:56:47Z","timestamp":1588762607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0800683X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":32,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0264410X0800683X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.05.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}